Study: Vaccine-induced antibody actually increases infectivity of SARS-CoV-2

Japanese paper first published December 18, 2020, shows when antibodies were made to the N-terminal domain (NTD) of the SARS-CoV-2 spike protein, it changed it’s structure and in doing so enhanced SARS-CoV-2 infectivity. Instead of “neutralising” the virus, the vaccine-induced antibodies made the virus more lethal. Meaning production of this antibody enhances the infectivity, a phenomenon referred to as Antibody Dependent Enhancement (ADE) or pathogenic priming.  [peer reviewed version]

The spike protein is made up of different epitopes or binding domains. If antibodies were made to the receptor binding domain (RBD) it’s been shown to prevent SARS-CoV-2 infection. This paper shows that antibodies made to the NTD epitope increases infectivity.

People who were hospitalised with severe COVID-19 had antibodies to this infectivity-enhancing NTD site.

All vaccines that have been approved by regulatory bodies code for this NTD region, something this paper warns should not be present in a new technology vaccines!

Watch @40min >>>